AzTrials
AzTrials

Aesthetic ProceduresNCT07261748

MENA Consensus on Poly-L-Lactic Acid (PLLA) Biostimulator Use in Aesthetic Dermatology

An observational study of Aesthetic Procedures and Cosmetic Techniques, run by Venus Research Center at 1 site in Egypt.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to develop expert consensus on the safe and effective use of poly-L-lactic acid (PLLA) biostimulators in aesthetic dermatology across the Middle East and North Africa (MENA) region. Read more about this study

Who is it for?
Ages 25 years and olderHealthy volunteers can take part
How many people
15 participants
Where
1 siteEgypt
Study dates
1 Nov 2025to Sep 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: A purposively selected group of dermatology and aesthetic medicine experts from Egypt and the broader MENA region. Participants are clinicians with significant experience using poly-L-lactic acid (PLLA) biostimulators and are invited to contribute to a structured Modified Delphi process to develop regional consensus recommendations.

Who may be able to join

  • Board-certified dermatologist or plastic surgeon OR physician practicing aesthetic medicine.
  • Minimum of 5 years of clinical experience OR ≥50 documented PLLA cases.
  • Practicing within Egypt or the Middle East and North Africa (MENA) region.
  • Willingness to participate in Delphi rounds and provide expert ratings.
  • Ability to read and respond to surveys in English.

Who cannot join

  • Inability or unwillingness to complete Delphi rounds.
  • Lack of clinical experience with PLLA.
  • Industry representatives without direct clinical practice.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Egypt1 site
  • Venus Research Center

    Cairo

Other trials in Egypt

About this study

This study aims to develop expert consensus on the safe and effective use of poly-L-lactic acid (PLLA) biostimulators in aesthetic dermatology across the Middle East and North Africa (MENA) region. PLLA is a commonly used injectable treatment that stimulates collagen production, but most guidelines come from Western populations and do not address the unique characteristics of Fitzpatrick III-VI skin types, which are predominant in the MENA region.

The study uses a Modified Delphi method, a well-established approach for collecting and refining expert agreement. Dermatologists and aesthetic physicians from MENA countries will participate in two to three online rounds of surveys. In Round 1, experts will answer open-ended questions about indications, contraindications, dilution techniques, safety concerns, anatomical considerations, and training needs related to PLLA. Their responses will be analyzed and converted into structured statements.

Read more

In Round 2, experts will rate each statement using a 1-to-9 Likert scale, indicating their level of agreement. Items with high agreement will form part of the final consensus. Statements with uncertain or conflicting ratings may undergo a third round for clarification.

No patients are involved in the study, and no treatments or interventions will be administered. The study collects professional opinions only, and all responses are anonymized during analysis. The final output will be a region-specific clinical guideline to support safer and more standardized PLLA use across the MENA region. Results will be published in peer-reviewed journals and shared with the aesthetic medical community.

Read the detailed description

Study Overview This study is a non-interventional, observational expert consensus project designed to develop region-specific guidelines for the use of poly-L-lactic acid (PLLA) biostimulators in aesthetic dermatology across the Middle East and North Africa (MENA) region. PLLA is widely used for collagen stimulation and facial rejuvenation, but existing evidence and guidelines are derived primarily from Western populations. Given that Fitzpatrick III-VI skin types dominate the MENA region, and that anatomical, cultural, and safety considerations differ, a structured expert consensus is required to optimize clinical practice.

Study Design

This study uses a Modified Delphi methodology, incorporating principles from the RAND/UCLA Appropriateness Method. The Delphi process includes 2-3 survey rounds:

Round 1 (Qualitative Item Generation):

Experts complete an open-ended questionnaire addressing indications, contraindications, dilution protocols, injection techniques, safety concerns (including risk of papules and PIH), anatomical considerations, combination treatments, follow-up practices, regulatory issues, training requirements, and research priorities. Responses undergo thematic analysis to generate structured candidate statements.

Round 2 (Quantitative Consensus Rating):

The consolidated statements are rated using a 9-point Likert scale (1 = inappropriate, 9 = appropriate). Experts rate each item independently based on clinical relevance, safety, and applicability in MENA populations.

Optional Round 3:

Statements without clear consensus are redistributed with anonymized group statistics for re-rating. This step is used only if needed to refine borderline items.

Expert Panel Selection

Experts will be eligible if they meet at least two of the following:

  • ≥5 years of aesthetic practice;
  • ≥50 PLLA cases performed;
  • Recognized trainer, lecturer, or KOL;
  • Publications or academic contributions in aesthetic medicine;
  • Active practice within Egypt or other MENA countries. Panel size will be 15-25 experts, ensuring geographic, academic, and experiential diversity.

Consensus Definitions

The study follows RAND/UCLA criteria:

  • Consensus (Appropriate): Median 7-9 AND Disagreement Index (DI) < 1.0
  • Consensus (Inappropriate): Median 1-3 AND DI < 1.0
  • No Consensus: Median 4-6 OR DI ≥ 1.0
  • Items with near-consensus may undergo a third Delphi round. Data Collection Tools

VRC-developed materials include:

  • Full A-L Likert questionnaire
  • Fillable PDF form
  • Online REDCap/Google Forms instrument
  • Round-2 survey booklet
  • Excel master sheet for response tracking Statistical Analysis For each item, the following will be calculated: median, interquartile range, interpercentile range (IPR), IPR adjusted for symmetry (IPRAS), and the Disagreement Index. Items will be categorized by agreement level and summarized for publication. Subgroup analyses (e.g., GCC vs North Africa) may be performed.

Ethical Considerations This study does not involve patients, clinical interventions, or personal health information. Participation is voluntary. Expert responses are anonymized. No foreseeable risks are associated with participation, and the study qualifies as minimal-risk, non-interventional research.

Outcomes and Dissemination The primary outcome is a set of consensus-based, region-specific recommendations for PLLA use in aesthetic practice. Secondary outcomes include identification of training standards and research priorities. Results will be disseminated through peer-reviewed publications, conference presentations, and a VRC-branded clinical guideline.

Keywords
Poly-L-lactic acid, PLLA, Biostimulator, Aesthetic dermatology, Collagen biostimulation, MENA region, Delphi study, Expert consensus, Cosmetic injectables, Facial rejuvenation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07261748
Study groupRoleWhat they receive
Expert PanelA cohort of dermatology and aesthetic medicine experts from the MENA region participating in a Modified Delphi process to develop consensus recommendations on PLLA biostimulator use.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Achievement of Consensus on PLLA Clinical Practice Statements

    The primary outcome is the proportion of Delphi statements reaching consensus among expert panelists. Consensus is defined using RAND/UCLA criteria: a median rating of 7-9 on a 9-point Likert scale with a Disagreement Index (DI) < 1.0. Statements will be categorized as "consensus appropriate," "consensus inappropriate," or "no consensus."

    Measured: 6-12 weeks

Secondary outcomes (1)
  1. Expert Rating Distribution Across PLLA Practice Domains

    Distribution of Likert scores (1-9) for each PLLA practice statement across domains (patient selection, dilution, technique, safety, anatomy, consent, combinations, ultrasound use, follow-up, regulatory, training, research priorities). Medians, interquartile ranges, and DI will be calculated.

    Measured: 6-12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Dec 2025
  2. Study start1 Nov 2025
  3. Primary completionJul 2026 (estimated)
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07261748
Sponsor's protocol ID
PLLA-VenusRC
Status last verified
Nov 2025
First submitted
22 Nov 2025
Last updated
3 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Delphi studies do not collect patient data, medical records, biological samples, or identifiable clinical information. Experts only give opinions, not "IPD." Their responses are anonymized, and sharing identifiable expert-level responses is not required and often discouraged

Questions about this trial

What is this clinical trial studying?

An observational study of Aesthetic Procedures and Cosmetic Techniques, run by Venus Research Center at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 3 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Achievement of Consensus on PLLA Clinical Practice Statements (time frame: 6-12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in